Coronavirus sector review: Matthews Asia reigns supreme as China funds best developed market rivals
The average IA China fund is down 0.6% compared with North America (-9.7%) and UK All Companies (-22.0%)
The average IA China fund is down 0.6% compared with North America (-9.7%) and UK All Companies (-22.0%)
Gilead Sciences has taken investors on a rollercoaster ride as it trials a treatment for the coronavirus
Fundsmith investment trust delivers less than half the 23% falls seen in the MSCI index
Growing fund universe has £6bn in AUM
Sector trailing other traditional late cycle winners despite strong earnings growth
Prothena also examines way forward for drug put on hold in 2018
MSCI World Health Care Index reaped positive returns as the wider market sold off
Aim-listed manager will issue up to four million new ordinary shares
BB Biotech managed to “weather the storm” that gripped the biotech sector in 2016 and beat its benchmark index, according to its latest annual report.
From betting on Europe over the US to sticking by emerging market debt, Portfolio Adviser considers five ways portfolio managers have stepped outside the box early on in 2017.
New products, strong finances and robust growth: the fundamental strength of the biotech sector was plain to see at JP Morgan’s annual conference for healthcare investors, but it was shrouded by the current political environment.
Neil Woodford expects returns from the bullish healthcare allocation in his three funds could now pick up following today’s win for Donald Trump.